| Name | Title | Contact Details |
|---|
Public Health Institute is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Octave Health is the nation`s first practice supporting all aspects of emotional well-being.
Fresenius Medical Care is the world`s leading provider of products and services for people with chronic kidney failure. Around 2.8 M patients with this disease worldwide regularly undergo dialysis treatment. Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure. We care for more than 300,000 patients in our global network of more than 3,500 dialysis clinics. At the same time, we operate ~ 40 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables. Our strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality. Fresenius Medical Care`s corporate headquarters are in Bad Homburg v.d.H., Germany. The headquarters of North America are in Waltham, Massachusetts and the headquarters of Asia-Pacific are located in Hong Kong.
Hematech, Inc was founded in 1998, with corporate headquarters in Sioux Falls, SD. Hematech is a subsidiary of Kyowa Hakko Kirin Company, Ltd. In 2002, Hematech and Kirin consolidated their transgenic bovine research programs in facilities in Sioux
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.